FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Conditions: Ovarian Cancer; Non-small Cell Lung Cancer Interventions: Drug: TUB-040 Sponsors: Tubulis GmbH Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Ovarian Cancer | Ovaries | Research | Study